An observational study in Pituitary Tumor and Visual Fields Hemianopsia, sponsored by University Medical Center Groningen. Not yet recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-23.
Sponsored by University Medical Center Groningen · Observational
The purpose of this study is to assess wether the SONDA visual field test is suitable for patients with a supra sellar tumour.
The objective of this study is to determine whether SONDA is non-inferior in predicting visual field limitations compared to the SAP in patients with a (supra)sellar tumor. The study population will be made up of patients with a (supra)sellar tumor complicated by compression of the optic chiasm as well as healthy controls. The patients will be asked to join the study when the patients are referred to the UMCG for further diagnostics and treatment. In case the patients show signs of visual field loss the patients will be asked to participate in the study. The researchers will reuse data from healthy controls collected in previous studies where possible and, if necessary for age matching, recruit new participants. Participants will be asked to perform the SONDA test before and after surgery. The first time the participants will perform the test twice and will also perform routine eye test and be asked to fill in a questionnaire to evaluate the experience.
200 studies on the registry are indexed under Pituitary Neoplasms; 51 are open to participants now.
This study's planned enrollment of 30 is below the median of 163 across 74 observational studies indexed under Pituitary Neoplasms.
Browse Pituitary Neoplasms studies →University Medical Center Groningen is the lead sponsor of 627 studies on the registry; 176 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with a (supra)sellar tumour and healthy controls
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants will undergo a visual acuity test. Next they will perform the SONDA test 2 times at one visit and once more in a later visit Participants will fill in a questionnaire
Diagnostic Test: SONDA
Participants will perform the SONDA test 2 times
Diagnostic Test: SONDA
Perimetry based visualfield analysis
Convert validity
Difference (dB) between the predicted MD (SONDA) and the assessed MD (SAP), expressed as delta MD.
Time frame: Baseline
Test-retest reliability
The variability of the predicted MD (dB) between consecutive measurements in the same person.
Time frame: baseline 1, baseline 2, 6-8 weeks post-operative
Experience
The experience of patients expressed in scores and descriptives based on a questionnaire: Questionnaire Standardized Oculomotor and Neuro-Ophthalmic Disorder Assessment
Time frame: Baseline
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Dec 2027, 12 months later.
Of 33 observational studies under Pituitary Neoplasms, half reached primary completion within 163 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 349. This study's planned 12 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Medical Center Groningen →